Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20198814 | 1.00 | BTK (0.59) | BTKMAP4K4SRCPIK3CDABL1 | |
| SCHEMBL20198837 | 0.93 | BTK (0.62) | BTKMAP4K4SRCEGFRRET | |
| SCHEMBL21378159 | 0.93 | BTK (0.62) | BTKMAP4K4SRCEGFRRET | |
| SCHEMBL17705887 | 0.91 | BTK (0.67) | BTKMAP4K4SRCEGFR | |
| SCHEMBL21391601 | 0.88 | BTK (0.78) | BTKEGFRRET | |
| SCHEMBL20198769 | 0.87 | BTK (0.75) | BTK | |
| SCHEMBL15984370 | 0.83 | BTK (0.50) | BTKMAP4K4SRCEGFRKDR | |
| SCHEMBL15491007 | 0.82 | BTK (0.55) | BTKMAP4K4EGFRRET | |
| SCHEMBL15220955 | 0.82 | BTK (0.55) | BTKMAP4K4EGFRRET | |
| SCHEMBL21391599 | 0.81 | BTK (0.59) | BTKEGFRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829491-B2 | Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD (CN) | 2020-11-10 | — | — | US | disclosed |
| US-20190292183-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-09-26 | — | — | US | disclosed |
| WO-2018095398-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292183-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | BTK, SYK, CDK8 | BTK 1/4885MAP4K4 1325/4885SRC 290/4885 |
| US-10829491-B2 | Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof | BTK, SYK, CDK8 | BTK 1/4885MAP4K4 1325/4885SRC 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.